WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsMangoceuticals, Inc. Common Stock (MGRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BrightSpring Health Services, Inc. Common Stock generates 4558983% more annual revenue ($14.37B vs $315,230). BTSG leads profitability with a 2.5% profit margin vs 0.0%. BTSG earns a higher WallStSmart Score of 55/100 (C).

BTSG

Buy

55

out of 100

Grade: C

Growth: 8.7Profit: 5.0Value: 4.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.59

MGRX

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: 2.57

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
196.6%10/10

Earnings expanding 196.6% YoY

Revenue GrowthGrowth
23.0%8/10

Revenue surging 23.0% year-over-year

MGRX2 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

BTSG4 concerns · Avg: 2.8/10
Profit MarginProfitability
2.5%3/10

2.5% margin — thin

Operating MarginProfitability
3.4%3/10

Operating margin of 3.4%

Debt/EquityHealth
1.173/10

Elevated debt levels

P/E RatioValuation
54.2x2/10

Premium valuation, high expectations priced in

MGRX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.42M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 23.0% demonstrates continued momentum.

Bull Case : MGRX

The strongest argument for MGRX centers on Price/Book, Debt/Equity.

Bear Case : BTSG

The primary concerns for BTSG are Profit Margin, Operating Margin, Debt/Equity. A P/E of 54.2x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.

Bear Case : MGRX

The primary concerns for MGRX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

BTSG profiles as a growth stock while MGRX is a value play — different risk/reward profiles.

MGRX carries more volatility with a beta of 2.10 — expect wider price swings.

BTSG is growing revenue faster at 23.0% — sustainability is the question.

BTSG generates stronger free cash flow (15M), providing more financial flexibility.

Bottom Line

BTSG scores higher overall (55/100 vs 23/100) and 23.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, focusing on diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation support. The company prioritizes personalized, high-quality care, facilitated by a dedicated and skilled workforce that significantly improves patient outcomes and quality of life. With robust investments in innovative technologies and a strong commitment to value-based care, BrightSpring is well-positioned to capitalize on growth opportunities within the dynamic healthcare landscape, highlighting its potential for sustainable, long-term success.

Visit Website →

Mangoceuticals, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Mangoceuticals, Inc. focuses to develop, market, and sell various men's wellness products and services through a telemedicine platform. The company is headquartered in Dallas, Texas.

Visit Website →

Want to dig deeper into these stocks?